Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma

Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma

Patients with advanced intrahepatic cholangiocarcinoma (iCCA) often have a poor prognosis. Recent advancements in targeted molecular therapy and immunotherapy have been made. Herein, we report a case of advanced iCCA treated with a combination of pemigatinib (a selective FGFR inhibitor), chemotherap...

Full description

Bibliographic Details
Main Authors:	Zhuochao Zhang, Gaofei Wang, Lei Du, Jie Zhao, Lichao Pan, Gong Zhang, Fei Wang, Rong Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-05-01
Series:	Frontiers in Immunology
Subjects:	advanced intrahepatic cholangiocarcinoma combined therapy FGFR inhibitors immune checkpoint inhibitor pemigatinib
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1124482/full

Similar Items

Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress
by: Gennaro Gadaleta-Caldarola, et al.
Published: (2022-10-01)

Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
by: Alessandro Rizzo
Published: (2021-05-01)

Clinical experience with pemigatinib for previously treated metastatic cholangiocarcinoma: practical considerations from clinical cases
by: Jonathan Wadsley, et al.
Published: (2023-08-01)

Multifocal serous retinopathy with pemigatinib therapy for metastatic colon adenocarcinoma
by: Oleg Alekseev, et al.
Published: (2021-04-01)

Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test
by: Shun Ishido, et al.
Published: (2023-07-01)

Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study
by: Guo‐Ming Shi, et al.
Published: (2023-02-01)

Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas
by: Xiaohong Pu, et al.
Published: (2023-11-01)

Case report: Pemigatinib-induced retinopathy: a serial examination of subretinal fluid secondary to an FGFR inhibitor
by: Daniel Barmas-Alamdari, et al.
Published: (2024-01-01)

Rare DNA Mismatch Repair-Related Protein Loss in Patients with Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma and Their Response to Immunotherapy
by: Yu J, et al.
Published: (2021-05-01)

Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations
by: Patrick C. Lee, et al.
Published: (2021-04-01)

Clinical management of intrahepatic cholangiocarcinoma: surgical approaches and systemic therapies
by: Samantha M. Ruff, et al.
Published: (2024-01-01)

Pulmonary Arterial Hypertension Induced by Immune Checkpoint Inhibitor Combined Therapy in a Patient with Intrahepatic Cholangiocarcinoma: A Case Report
by: Jingjing Zhang, et al.
Published: (2023-06-01)

New Era of Immune-Based Therapy in Intrahepatic Cholangiocarcinoma
by: Etsushi Kawamura, et al.
Published: (2023-08-01)

FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice
by: Anuhya Kommalapati, et al.
Published: (2021-06-01)

Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis
by: Xue-Gang Yang, et al.
Published: (2022-07-01)

Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs
by: Angelica Pace, et al.
Published: (2023-09-01)

Camrelizumab plus gemcitabine and oxaliplatin for the treatment of advanced intrahepatic cholangiocarcinoma: a bi-centric observational retrospective study
by: Yu-Qing Zhang, et al.
Published: (2023-05-01)

A Robust FISH Assay to Detect FGFR2 Translocations in Intrahepatic Cholangiocarcinoma Patients
by: Lei Zhang, et al.
Published: (2023-06-01)

SARCOMATOID CHANGE IN INTRAHEPATIC CHOLANGIOCARCINOMA
by: Wewer Albrechtsen, et al.
Published: (2013-01-01)

Sarcomatoid change in intrahepatic cholangiocarcinoma
by: Albrechtsen Wewer Nicolai, et al.
Published: (2013-03-01)

Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration
by: Zi-Rong Chen, et al.
Published: (2023-09-01)

FIGHT‐102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies
by: Yutaka Fujiwara, et al.
Published: (2023-05-01)

Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review
by: Peiyi Xie, et al.
Published: (2022-08-01)

The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting
by: Salati M, et al.
Published: (2021-10-01)

Intrahepatic Cholangiocarcinoma with Sarcomatous Changes
by: Yoshiyuki Inoue, et al.
Published: (2012-01-01)

The 8p11 myeloproliferative syndrome: Genotypic and phenotypic classification and targeted therapy
by: Taotao Li, et al.
Published: (2022-11-01)

Formulation development, optimization and characterization of Pemigatinib-loaded supersaturable self-nanoemulsifying drug delivery systems
by: Muthadi Radhika Reddy, et al.
Published: (2022-11-01)

Hepatectomy or/with Metastatectomy for Recurrent Intrahepatic Cholangiocarcinoma: Of Promise for Selected Patients
by: Chun-Yi Tsai, et al.
Published: (2022-03-01)

PIWIL4 and SUPT5H combine to predict prognosis and immune landscape in intrahepatic cholangiocarcinoma
by: Wenbo Zou, et al.
Published: (2021-12-01)

The focus clinical research in intrahepatic cholangiocarcinoma
by: Yinghui Song, et al.
Published: (2022-07-01)

A novel nomogram for the prediction of intrahepatic cholangiocarcinoma in patients with intrahepatic lithiasis complicated by imagiologically diagnosed mass
by: Chen G, et al.
Published: (2018-04-01)

Lenvatinib Combined With a PD-1 Inhibitor as Effective Therapy for Advanced Intrahepatic Cholangiocarcinoma
by: Lulu Xie, et al.
Published: (2022-06-01)

Role of Percutaneous Ablation in the Management of Intrahepatic Cholangiocarcinoma
by: Georgios Charalampopoulos, et al.
Published: (2023-06-01)

Changing Landscape of Systemic Therapy in Biliary Tract Cancer
by: Edward Woods, et al.
Published: (2022-04-01)

Resection of intrahepatic cholangiocarcinoma in elderly patients – is it reasonable?
by: Fabian Bartsch, et al.
Published: (2019-10-01)

Challenges and Opportunities for Treating Intrahepatic Cholangiocarcinoma
by: Serifis N, et al.
Published: (2021-11-01)

A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality
by: Jain Nem Kumar, et al.
Published: (2024-03-01)

iNOS is Associated with Tumorigenicity as an Independent Prognosticator in Human Intrahepatic Cholangiocarcinoma [Retraction]
by: Liu S, et al.
Published: (2023-08-01)

Immunotherapy in cholangiocarcinoma: From concept to clinical trials
by: Wen-Yan Yao, et al.
Published: (2021-06-01)

Vascular Resection for Intrahepatic Cholangiocarcinoma: Current Considerations
by: Ruslan Alikhanov, et al.
Published: (2021-08-01)